Pfizer Says CMA Failed To Consider Benefits Of Epilepsy Drug
Pfizer said Monday that the Competition and Markets Authority didn't consider the value of its anti-epilepsy drug to the National Health Service when looking at its price, as it fights to...To view the full article, register now.
Already a subscriber? Click here to view full article